Mapping the Progress of Alzheimer's and Parkinson's Disease

by Mizuno, Yoshikuni; Fisher, Abraham; Hanin, Israel

• ISBN13: 9780306467639
• ISBN10: 0306467631
• Format: Hardcover
• Copyright: 2002-03-01
• Publisher: Plenum Pub Corp

Summary

This book is the proceedings of the highly successful 5th International Conference on Progress in Alzheimer's Disease and Parkinson's Disease which took place from March 31st to April 5th, 2001, in Kyoto, Japan. This international conference was organized as a joint Congress with the 9th International Catecholamine Symposium, and included a total of 1258 clinicians and researchers from 38 countries throughout the world. This meeting was an extremely good opportunity for investigators and clinicians to meet and discuss with people who were working in somewhat different but closely related fields, and to exchange their scientific knowledge and experiences.

Table of Contents

PROGRESS IN ALZHEIMER'S DISEASE
ETIOLOGY AND PATHOGENESIS OF ALZHEIMER'S DISEASE
Cell Biology of Amyloidogenesis: an Overview	1	(6)
Dennis l. Selkoe
Weiming Xia
W. Taylor Kimberly
Konstantinos Vekrellis
Dominic Walsh
William Esler
Michael S. Wolfe
Alzheimer's Disease as a Proteolytic Disorder: Catabolism and Processing of Amyloid β-Peptide	7	(6)
Nobuhisa Iwata
Takaomi C. Saido
Amyloidogenesis and Cholesterol	13	(6)
Katsuhiko Yanagisawa
Katsumi Matsuzaki
Toxicity of App Fragments	19	(8)
Yoo-Hun Suh
Ji-Heui Seo
Yanji Xu
Chaejeong Heo
Najung Kim
Jun Ho Choi
Se Hoon Choi
Jong-Cheol Rah
Keun-A Chang
Won-Hyuk Suh
Significance of Neurofibrillary Tangles in Alzheimer's Disease Lessons From Frontotemporal Dementia and Parkinsonism Linked to Chromosome 17	27	(6)
Yasuo Ihara
The Effects of Apolipoprotein E Genotype on Brain Lipid Metabolism	33	(6)
Alisa Tietz
Leah Oron
Eliezer Mazliah
Daniel M. Michaelson
Apolipoprotein E: a Novel Therapeutic Target for the Treatment of Alzheimer's Disease	39	(6)
Judes Poirier
Michel Panisset
Antisense Intervention with Cholinergic Impairments Associated With Neurodegenerative Disease	45	(4)
Eran Meshorer
Hermona E. Soreq
Neuronal Survival and Death in Alzheimer Disease	49	(10)
Arun K. Raina
Catherine A. Rottkamp
Xiongwei Zhu
Osama Ogawa
Ayala Hochman
Shun Shimohama
Atsushi Takeda
Akihiko Nonomura
George Perry
Mark A. Smith
The Histamine-Cytokine Network in Alzheimer Disease: Etiopathogenic and Pharmacogenomic Implications	59	(6)
Ramon Cacabelos
FAMILIAL ALZHEIMER'S DISEASE AND BIOLOGY OF PRESENILINS
Presenilin and Amyloidogenesis: a Structure-Function Relationship Study on Presenilin 2	65	(8)
Takeshi Iwatsubo
Taisuke Tomita
Tomonari Watabiki
Rie Takikawa
Yuichi Morohashi
Nobumasa Takasugi
PS1 Interacts With and Facilitates β-Catenin Turnover	73	(6)
Edward H. Koo
Salvador Soriano
David E. Kang
β-Secretase - a Target for Alzheimer's Disease	79	(6)
Martin Citron
Cell Biology of Presenilins	85	(6)
Seong-Hun Kim
Sangram S. Sisodia
Presenilin Dependent Y-Secretase Processing of &-Amyloid Precursor Protein at a Site Corresponding to the S3 Cleavage of Notch	91	(4)
Harald Steiner
Magdalena Sastre
Gerd Multhaup
David B. Teplow
Christian Haass
Endoplasmic Reticulum Stress and Alzheimer's Disease	95	(6)
Takashi Kudo
Taiichi Katayama
Kazunori Imaizumi
Yuka Yasuda
Misako Yatera
Masayasu Okochi
Toshihisa Tanaka
Kojin Kamino
Masaya Tohyama
Masatoshi Takeda
Ps-I Is Transported From the Moto-Neurons to Their Axon Terminals	101	(4)
Peter Kasa
Henrietta Papp
Magdolna Pakaski
Calsenilin-Presenilin Interaction in Alzheimer's Disease	105	(6)
Eun-Kyoung Choi
Joseph D. Buxbaum
Wilma Wasco
Presenilin-1 Function in the Adult Brain	111	(6)
Jie Shen
ANIMAL MODELS OF ALZHEIMER'S DISEASE
Neuropeptide Expression in Animal Disease Models	117	(4)
Tomas Hokfelt
Margarita Diez
Tiejun Shi
Jari Koistinaho
Dora Games
Karen Kahn
Bernd Sommer
Karl-Heinz Wiederhold
Simone Danner
Role of Inducible Nitric Oxide Synthase In β-Amyloid- Induced Brain Dysfunction in Rats	121	(6)
Kiyofumi Yamada
Manh Hung Tran
Hyoung-Chun Kim
Toshitaka Nabeshima
Amyloid Pathology and Cholinergic Networks in Transgenic Models of Alzheimer's Disease	127	(6)
A. Claudio Cuello
Mechanism of Neuronal Death in Alzheimer's Disease: a Transgenic Mouse Perspective	133	(6)
Michael C. Irizarry
Interactions of Beta-Amyloid with the Formation of Neurofibrillary Tangles in Transgenic Mice	139	(6)
Jurgen Gotz
Feng Chen
Roger M. Nitsch
GLYCOSAMINOGLYCANS (GAGS) IN ALZHEIMER'S DISEASE
Historical Overview of Glycosaminoglycans (Gags) and Their Potential Value in the Treatment of Alzheimer's Disease	145	(12)
U. Cornelli
I. Hanin
S. Lorens
J. Fareed
J. Lee
R. Mervis
P. Piccolo
M. Cornelli
Glycosaminoglycans and Glycomimetics: Potential Role in the Management of Alzheimer's Disease	157	(8)
Qing Ma
Jawed Fareed
Bertalan Dudas
Umberto Cornelli
John Lee
Israel Hanin
Low Molecular Weight Glycosaminoglycan Blockade of Beta Amyloid (25-35) Induced Neuropathology	165	(6)
M. Walzer
S. Lorens
M. Hejna
J. Fareed
R. Mervis
I. Hanin
U. Cornelli
J. M. Lee
C3, A Promising Ultra Low Molecular Weight Glycosaminoglycan for the Treatment of Alzheimer's Disease	171	(6)
Israel Hanin
Bertalan Dudas
Ronald F. Mervis
Umberto Cornelli
John M. Lee
Stanley A. Lorens
Jawed Fareed
CLINICAL EVALUATION OF ALZHEIMER'S DISEASE
Mild Cognitive Impairment	177	(6)
Vesna Jelic
Bengt Winblad
Functional Activation Studies in Alzheimer Patients and Strategies in Drug Evaluation	183	(4)
Agneta Nordberg
PROGRESS IN THE TREATMENT OF ALZHEIMER'S DISEASE
Structural and Functional Correlates of Human Acetylcholinesterase Mutants for Evaluating Alzheimer's Disease Treatments: Functional Analysis of E2020 and Galanthamine Huache Complexes	187	(6)
Avigdor Shafferman
Dov Barak
Arie Ordentlich
Naomi Ariel
Chanoch Kionman
Dana Kaplao
Baruch Velan
The New Generation of Acetylcholinesterase Inhibitors	193	(6)
Hachiro Sugimoto
Yoichi Iimura
Yoshiharu Yamanishi
Tv3326, a Novel Cholinesterase and Mao Inhibitor: for Alzheimer's Disease with Co-Morbidity of Parkinson's Disease and Depression	199	(6)
Marta Weinstock
Tatyana Poltyrev
Corina Bejar
Yotam Sagi
Moussa B. H. Youdim
NOVEL DRUG TREATMENT OF ALZHEIMER'S DISEASE: BEYOND CHOLINESTERASE INHIBITORS
Ml Muscarinic Agonists as a Therapeutic Strategy in Alzheimer's Disease: Ml Muscarinic Agonists in Alzheimer's Disease	205	(6)
Abraham Fisher
Zipora Pittel
Rachel Haring
Rachel Brandeis
Nira Bar-Ner
Hagar Sonego
Itzhak Marcovitch
Niva Natan
Nadine Mestre-Frances
Noeile Bons
Phenserine Regulates Translation of β-Amyloid Precursor Protein Message: a Novel Drug Target for Alzheimer's Disease	211	(6)
D. K. Lahiri
T. Utsuki
K. T. Y. Shaw
Y.-W. Ge
K. Sambamurti
P. S. Eder
J. T. Rogers
M. R. Farlow
T. Giordino
N. H. Greig
The Forkhead Family of Transcription Factors are Targets of Akt in Igf-1 Mediated Survival in Neuronal Cells	217	(6)
Wen-Hua Zheng
Satyabrata Kar
Remi Quirion
NEW TREATMENT ON THE HORIZON IN ALZHEIMER'S DISEASE
Development of Anti-Dementia Drugs for Alzheimer's Disease: Present and Future	223	(6)
Toshitaka Nabeshima
Kiyofumi Yamada
Human Neural Stem Cell Transplantation Improves Cognitive Function of Aged Brain: Possibility of Neuroreplacement Therapy	229	(6)
Kiminobu Sugaya
Tingyu Qu
Hojoong M. Kim
Christopher L. Brannen
Bip/GRP78-Induced Microglial Activation and Increase of Aβ Clearance	235	(4)
Yoshihisa Kitamura
Jun-ichi Kakimura
Takashi Tamguchi
Shun Shunohama
Peter J. Gebicke-Haerter
PROGRESS IN PARKINSON'S DISEASE
ETIOLOGY AND PATHOGENESIS
Etiology, Pathogenesis, and Genetics of Parkinson's Disease	239	(6)
Yoshikuni Mizuno
Nobutaka Hattori
Hideki Shimura
Tohru Kitada
Shin-ichiro Kubo
Mei Wang
Ken-ichi Sato
Toshiaki Suzuki
Tomoki Chiba
Keiji Tanaka
Shuichi Asakawa
Shinsei Minoshuna
Nobuyoshi Shimizu
Parkinson's Disease, Neurotoxins and the Dopamine Transporter: Evidence from Classical Brain Dopamine Studies	245	(6)
Oleh Hornykiewicz
Genetic Risk Factors in Parkinson's Disease	251	(8)
Kin-Lun Tsang
Zhe-Hui Feng
Hong Jiang
David B. Ramsden
Shu-Leong Ho
Inflammatory Changes and Apoptosis in Parkinson's Disease	259	(6)
Etienne C. Hirsch
Cytokines and Neurotrophins in Parkinson's Disease: Involvement in Apoptosis	265	(6)
Toshiharu Nagatsu
Makio Mogi
Hiroshi Ichinose
Akifumi Togari
Chronic Complex 1 Inhibition Reproduces Features of Parkinson's Disease Pesticides And Parkinson's Disease	271	(6)
Todd B. Sherer
Ranjita Betarbet
J. Timothy Greenamyre
Neutral (R)Salsolinol N-Methyl-Transferase as a Pathogenic Factor of Parkinson's Disease	277	(4)
Wakako Maruyama
Takako Yamada
Yukihiko Washimi
Teruhiko Kachi
Nobuo Yanagisawa
Fujiko Ando
Hitoshi Shimokata
Makoto Naoi
FAMILIAL PARKINSON'S DISEASE
Familial Variants of Parkinson's Disease	281	(4)
Katrina Gwinn-Hardy
Melissa Hanson
Zbigniew Wszolek
Amanda Adam
Andrew Singleton
Charles H. Adler
John N. Caviness
James Bower
Steven Hickey
Judy Ying Chen
Shamaila Waseem
Matt Farrer
Familial Parkinsonism with Apathy, Depression and Central Hypoventilation (Perry's Syndrome)	285	(6)
Bulent Elibol
Tomonori Kobayashi
F. Belgin Atac
Nobutaka Hattori
Gurdal Sahin
Gunfer Gurer
Yoshikuni Mizuno
Ubiquitin-Proteasome Pathway is a Key to Understanding of Nigral Degeneration in Autosomal Recessive Juvenile Parkinson's Disease	291	(6)
Nobutaka Hattori
Shuichi Asakawa
Hideki Shimura
Shin-ichiro Kubo
Kenichi Sato
Toshiaki Kitami
Yoko Chikaoka-Kawamura
Yuzuru Imai
Ryosuke Takahashi
Toshiaki Suzuki
Keiji Tanaka
Nobuyoshi Shimizu
Yoshikuni Mizuno
Colocalization of Parkin with α-Synuclein in the Lewy Bodies of Parkinson Disease	297	(4)
Michael G. Schlossmacher
Matthew P. Frosch
Wei Ping Gai
Nutan Sharma
Miguel Medina
Tomoyo Ochiishi
Hideki Shimura
Nobutaka Hattori
Yoshikuni Mizuno
Bradley T. Hyman
Dennis J. Selkoe
Kenneth S. Kosik
Ubiquitination of a Novel Form of A-Synuclein by Parkin	301	(4)
Hideki Shimura
Michael G. Schlossmacher
Nobutaka Hattori
Matthew P. Frosch
Alexander Trockenbacher
Rainer Schneider
Yoshikuni Mizuno
Kenneth S. Kosik
Dennis J. Selkoe
CLINICAL TOPICS IN PARKINSON'S DISEASE
A Short History of Dopamine and Levodopa in Parkinson's Disease	305	(6)
Reinhard Horowski
Famous People with Parkinson Disease	311	(4)
Abraham Lieberman
Historical Aspects of Parkinson's Disease in Japan	315	(6)
Kunio Tashiro
Clinical Evaluation and Differential Diagnosis of Parkinsonism	321	(4)
Philip D. Thompson
The Natural History and Prognosis of Parkinson's Disease	325	(4)
Werner Poewe
Gait Disturbances in Parkinson's Disease	329	(8)
Nir Giladi
Jacov Balash
Jeffrey M. Hausdorff
Levodopa Does Not Enhance Nigral Degeneration	337	(6)
Ali H. Rajput
Dementia in Idiopathic Parkinson's Syndrome	343	(6)
Heinz Reichmann
Ulrike Sommer
Autonomic Disorders and Malignant Syndrome in Parkinson's Disease	349	(4)
Sadako Kuno
Progress in Segawa's Disease	353	(8)
Masaya Segawa
PROGRESS IN THE TREATMENT OF PARKINSON'S DISEASE
Progress in the Treatment of Parkinson's Disease	361	(4)
Donald B. Calne
Theoretical Consideration of Drug Therapy in Parkinson's Disease	365	(8)
Jin-Soo Kim
Young H. Sohn
Neuroprotection in Parkinson's Disease	373	(6)
L. V. Prasad Korlipara
Anthony H. V. Schapira
DOPAMINE AGONISTS
Sustained Dopamine Agonism with Cabergoline in Parkinson's Disease: Evolution of Therapy From Animal Models to Man	379	(6)
Linda S. Appiah-Kubi
K. Ray Chaudhuri
Sleepiness and Sleep Attacks in Parkinson's Disease	385	(6)
Anette V. Nieves
Anthony E. Lang
Neuroprotection by Dopamine Agonists and Application of Immunophilin Ligands	391	(6)
Tomoyoshi Kondo
MECHANISM AND TREATMENT OF MOTOR COMPLICATIONS
Problems of Long-Term Levodopa Treatment	397	(6)
Fabrizio Stocchi
Evaluation of Abnormal Involuntary Movements in Parkinson's Disease	403	(6)
Hakan Widner
Medical Treatment of L-Dopa-Induced Dyskinesias	409	(8)
Olivier Rascol
Christine Brefel-Courbon
P. Payoux
Joaquim F. Ferreira
TREATMENT OF DEPRESSION AND COGNITIVE DYSFUNCTION IN PARKINSON'S DISEASE
Management of Anxiety and Depression in Parkinson's Disease	417	(6)
Bhim S. Singhal
Jamshed A. Lalkaka
Ashit Sheth
Tandospirone Citrate, a New Serotonergic Anxiolytic Agent: a Potential Use in Parkinson's Disease	423	(6)
Yukihiro Ohno
SURGICAL TREATMENT OF PARKINSON'S DISEASE
Stereotactic Surgery of Parkinson's Disease Over 30 Years	429	(6)
Chihiro Ohye
Surgical Treatment for Dyskinesias	435	(6)
Andres M. Lozano
Hazem A. Eltahawy
Deep Brain Stimulation and Neuroprotection	441	(14)
Alim-Louis Benabid
Brigitte Piallat
Abdelhamid Benazzouz
Adnan Koudsie
Stephan Chabardes
Pierre Pollak
Doris Lenartz
Chtistian Andressen
NEW TREATMENT ON THE HORIZON IN PARKINSON'S DISEASE
Cyclic Gmp-Mediated Preconditioning Gene Induction as a Treatment of Alzheimer's Dementia and Parkinson's Disease	447	(8)
Chuang Chin Chiueh
Tsugunobu Andoh
Neuroprotective Properties of Gp11046, a Non-Immunosuppressive Immunophilin Ligand	455	(4)
Ken-ichi Tanaka
Norio Ogawa
Gene Therapy for Parkinson's Disease Using Aav Vectors	459	(4)
Keiya Ozawa
Shin-ichi Muramatsu
Ken-ichi Fujimoto
Kunihiko Ikeguchi
Yang Shen
Lijun Wang
Takashi Okada
Hiroaki Mizukami
Yutaka Hanazono
Akihiro Kume
Hiroshi Ichinose
Toshiharu Nagatsu
Keiji Terao
Imaharu Nakano
Fk506 Protects Dopaminergic Degeneration through Induction of Gdnf in Rodent Brains: New Treatments on the Horizon In Parkinson's Disease	463	(6)
Atsumi Nitta
Rina Murai
Keiko Maruyama
Shoei Furukawa
Anti-Apoptotic Therapy for Parkinson's Disease: Overexpression of an Apaf-1-Dominant-Negative Inhibitor can Block Mptp Toxicity	469	(4)
Hideki Mochizuki
Hideki Hayakawa
Makoto Migita
Takashi Shimada
Masayuki Miura
Yoshikuni Mizuno
DEMENTIA WITH LEWY BODIES
Clinical Diagnostic Classification of Dementia with Lewy Bodies	473	(4)
Daniel I. Kaufer
Neuropathology of Dementia with Lewy Bodies	477	(6)
Kenji Kosaka
Eizo Iseki
Molecular Biology of Lewy Body Formation: α-Synucleinopathies	483	(8)
Maria Grazia Spillantini
George K. Tofaris
Cholinergic and Monoaminergic Correlates of Clinical Symptoms in Dementia With Lewy Bodies	491	(6)
Elaine K. Perry
Margaret A. Piggott
Mary Johnson
Clive G. Ballard
Ian G. MeKeith
Evelyn Jaros
Robert H. Perry
Molecular Biology of A-Synuclein: Dementia with Lewy Bodies	497	(12)
Olaf Riess
Rejko Kruger
Hirokazu Kobayashi
Carsten Holzmann
Nobutaka Hattori
Yoshikuni Mizuno
Accumulation of Insoluble α-Synuclein in Human Lewy Body Diseases is Recapitulated in Transgenic Mice	509	(4)
Philipp J. Kahle
Manuela Neumann
Laurence Ozmen
Takeshi Iwatsubo
Hans A. Kretzschmar
Christian Haass
Alternative Treatments for Lewy Body Disease in Transgenic Mice: Dementia With Lewy Bodies	513	(4)
Manfred Windisch
Edward Rockenstein
Makoto Hashimoto
Margaret Mallory
Eliezer Masliah
FAMILIAL FRONTOTEMPORAL DEMENTIA AND RELATED DISORDERS
Familial Frontotemporal Dementia and Parkinsonism (Ftdp-17): A Consensus on Clinical Diagnostic Criteria	517	(6)
Zbigniew K. Wszolek
Yoshio Tsuboi
The Neuropathology of Frontotemporal Lobar Degeneration	523	(8)
David M. A. Mann
Stuart M. Pickering-Brown
Progress in Psp and Cbd	531	(6)
D. W. Dickson
K. lshizawa
T. Togo
M. Baker
J. Adamson
M. Hutton
W.-K. Liu
S.-H. Yen
Biochemical Analysis of Tau And α-Synuclein in Neurodegenerative Diseases	537	(6)
Masato Hasegawa
Sayuri Taniguchi
Hirofumi Aoyagi
Hideo Fujiwara
Takeshi Iwatsubo
Production and Analysis of Human Mutant Tau (V337m) Transgenic Mouse	543	(6)
Akihiko Takashima
Kentaro Tanemura
Index	549